Physician profile
William Nash
NPI 1235172628
$1,079.56
in general payments reported to CMS, 2019-2025
19 companies · $64.88 in 2025
The $64.88 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.06 · 2020: $92.91 · 2021: $64.05 · 2022: $545 · 2023: $215 · 2024: $41.19 · 2025: $64.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $321.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $166.77 | 2022-2025 | Nuplazid |
| Amgen INC. | $129.93 | 2019-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $124.03 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $92.88 | 2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $78.46 | 2022 | |
| Lilly USA, LLC | $76.74 | 2020-2025 | Mounjaro |
| Xeris Pharmaceuticals, INC. | $74.02 | 2022 | |
| Novo Nordisk INC | $53.73 | 2020-2024 | Ozempic, Rybelsus |
| Mylan Specialty L.P. | $49.99 | 2023 | Yupelri |
| Urovant Sciences INC | $47.19 | 2022 | |
| Dexcom, INC. | $39.88 | 2022 | |
| Biogen, INC. | $26.07 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $23.64 | 2023 | Aptiom |
| Avanir Pharmaceuticals, INC. | $20.06 | 2019 | |
| Glaxosmithkline, LLC. | $16.42 | 2023 | Arexvy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $16.20 | 2023 | Quviviq |
| Abbvie INC. | $16.14 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2020 | |
| Athena Bioscience, LLC | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Nash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.